Response to interferon-α2a in patients with e antigen-negative chronic hepatitis B

Journal of Clinical Gastroenterology

Volumn 25, Issue 2, 1997, Pages 440-445

  Kako, Makoto ^a,i   Kanai, Koichi ^b   Aikawa, Tatsuya ^c   Iwabuchi, Shogo ^d   Takehira, Yasunori ^e   Kawasaki, Tsunehisa ^f   Tsubouchi, Hirohito ^g   Hino, Kunihiko ^h   Tsuda, Fumio ^b   Okamoto, Hiroaki ⁱ   Miyakawa, Yuzo ^j   Mayumi, Makoto ⁱ  

^a TEIKYO UNIVERSITY MIZONOKUCHI HOSPITAL   (Japan)

^b Shinagawa ku   (Japan)

^c Aikawa Internal Medicine Hospital   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HAMAMATSU MEDICAL CENTER   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF MIYAZAKI   (Japan)

^h NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

^j Miyakawa Memorial Research Foundation   (Japan)

more..

Author keywords

Hepatitis B; Hepatitis B e antigens; Hepatitis B virus; Interferons

Indexed keywords

ALPHA2A INTERFERON; HEPATITIS E ANTIGEN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0030723004     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199709000-00009     Document Type: Article

References (36)

1. Tine F, Liberati A, Craxi A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J Hepatol 1993;18:154-62.
2. Ryff JC. To treat or not to treat? The judicious use of interferon-alpha-2a for the treatment of chronic hepatitis B. J Hepatol 1993;17:S42-6.
3. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
4. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989;10:198-202.
5. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990;11:S133-6.
6. Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992;15:584-9.
7. Pastore G, Santantonio T, Milella M, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992;14:221-5.
8. Alberti A, Fattovich G. Interferon therapy for the anti-HBe positive form of chronic hepatitis B. Antiviral Res 1994;24:145-53.
9. Bayraktar Y, Koseoglu T, Temizer A, Kayhan B, Van TD, Uzunalimoglu B. Relationship between the serum alanine aminotransferase level at the end of interferon treatment and histologic changes in wild-type and precore mutant hepatitis B virus infections. J Viral Hepatitis 1996;3:137-42.
10. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-91.
11. Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990;64:1298-303.
12. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993;105:845-50.
13. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
14. Aikawa T, Kanai K, Kako M, et al. Interferon-α2a for chronic hepatitis B with e antigen or antibody: comparable antiviral effects on wild-type virus and precore mutant. J Viral Hepatitis 1995;2:243-50.
15. De Groote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968;2:626-8.
16. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
17. Kanal K, Kako M, Aikawa T, et al. Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B. Am J Gastroenterol 1996;91:2150-6.
18. Iizuka H, Ohmura K, Ishijima A, et al. Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg. Vox Sang 1992;63:107-11.
19. Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994;68:8102-10.
20. Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-8.
21. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-8.
22. Realdi G, Alberti A, Rugge M, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980;79:195-9.
23. Marcellin P, Martinot PM, Loriot MA, et al. Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. Ann Intern Med 1990;112:227-8.
24. Carman WF, Dourakis S, Karayiannis P, Crossey M, Drobner R, Thomas HC. Incidence of hepatitis B viraemia, detected using the polymerase chain reaction, after successful therapy of hepatitis B virus carriers with interferon-alpha. J Med Virol 1991;34:114-8.
25. Molina J, Bartolome J, Moraleda G, et al. Persistence of hepatitis B virus DNA after reduction of viral replication in serum and liver. J Med Virol 1992;38:11-5.
26. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983;3:656-62.
27. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986;90:1268-73.
28. Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988;8:1651-4.
29. Akahane Y, Yamanaka T, Suzuki H, et al. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990;99:1113-9.
30. Brunetto MR, Stemler M, Bonino F, et al. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 1990;10:258-61.
31. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996;48:8-16.
32. Fattovich G, McIntyre G, Thursz M, et al. Hepatitis B virus precore core variation and interferon therapy. Hepatology 1995;22: 1355-62.
33. Yaginuma K, Shirakata Y, Kobayashi M, Koike K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci USA 1987;84:2678-82.
34. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-51.
35. Yu X, Mertz JE. Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. J Virol 1996;70:8719-26.
36. 1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995;76:3159-64.